PHOENIX--(BUSINESS WIRE)--Provista Life Sciences LLC (PLS), a diagnostic development and commercialization company, announced today it has successfully completed extensive clinical trials on a new blood test for the early detection of breast cancer. The test is called the BT Test™ and it is being made available to a select number of physicians in the Phoenix market as part of the company’s initial market release. The BT Test, which stands for Biomarker Translation Test, is designed to assist physicians in making an earlier and more accurate diagnosis of breast cancer when used adjunctively with a mammogram.
